UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interpreting the LHC Higgs search results in the MSSM

Physics letters. B, 2012-03, Vol.710 (1), p.201-206

2012

Volltextzugriff (PDF)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Annals of oncology, 2013-08, Vol.24 (8), p.1994-1999

2013

Volltextzugriff (PDF)

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Journal of clinical oncology, 2022-12, Vol.40 (35), p.4071-4082

2022

Volltextzugriff (PDF)

Proteomics-based characterization of potential biomarkers in tamoxifen resistance in breast cancer

JOURNAL OF CLINICAL ONCOLOGY, 2011, Vol.29 (15_suppl), p.628-628

2011

Volltextzugriff (PDF)

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

BMC cancer, 2014-02, Vol.14 (1), p.119-119, Article 119

2014

Volltextzugriff (PDF)

IP6K2 predicts favorable clinical outcome of primary breast cancer

Molecular and clinical oncology, 2021-05, Vol.14 (5), p.94-94, Article 94

2021

Volltextzugriff (PDF)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Molecular and clinical oncology, 2020, Vol.12 (5), p.415-420

2020

Volltextzugriff (PDF)

S-phase fraction is a prognostic factor in stage I breast carcinoma

Journal of clinical oncology, 1993-09, Vol.11 (9), p.1717-1722

1993

Volltextzugriff (PDF)

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

BMC cancer, 2021-02, Vol.21 (1), p.185-185, Article 185

2021

Volltextzugriff (PDF)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

Breast cancer research and treatment, 2013-01, Vol.137 (2), p.397-406

2013

Volltextzugriff (PDF)

C-erbB-2 overexpression and survival in early onset breast cancer

Breast cancer research and treatment, 2000-09, Vol.63 (1), p.23-29

2000

Volltextzugriff (PDF)

Expression of COX-2 and steroid converting enzymes in breast cancer

Oncology reports, 2006-08, Vol.16 (2), p.219-224

2006

Volltextzugriff (PDF)

Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer

PloS one, 2012-09, Vol.7 (9), p.e45669-e45669

2012

Volltextzugriff (PDF)

Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial

JOURNAL OF CLINICAL ONCOLOGY, 2018, Vol.36 (15_suppl), p.541-541

2018

Volltextzugriff (PDF)

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer

PloS one, 2012, Vol.7 (7), p.e40568-e40568

2012

Volltextzugriff (PDF)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

Oncology letters, 2020-01, Vol.19 (1), p.52-60

2020

Volltextzugriff (PDF)

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

Clinical proteomics, 2015-03, Vol.12 (1), p.8-8, Article 8

2015

Volltextzugriff (PDF)

Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer

Journal of clinical oncology, 2005-07, Vol.23 (21), p.4695-4704

2005

Volltextzugriff (PDF)

c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 1995-01, Vol.103 (1-6), p.309-315

1995

Volltextzugriff (PDF)

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up

Breast cancer research and treatment, 2013-04, Vol.138 (2), p.467-473

2013

Volltextzugriff (PDF)

HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen

International journal of oncology, 2015-10, Vol.47 (4), p.1311-1320

2015

Volltextzugriff (PDF)

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

European journal of cancer (1990), 2013-04, Vol.49 (6), p.1196-1204

2013

Volltextzugriff (PDF)

A comparison between flow cytometric assessment of S-phase fraction and Nottingham histologic grade as prognostic instruments in breast cancer

Breast cancer research and treatment, 2000-09, Vol.63 (1), p.11-15

2000

Volltextzugriff (PDF)

Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients

Oncology reports, 2013-04, Vol.29 (4), p.1467-1474

2013

Volltextzugriff (PDF)

Cytoplasmic p21 WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer

International journal of oncology, 2006, Vol.28 (5), p.1031

2006

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(52)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Interpreting the LHC Higgs search results in the MSSM

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Proteomics-based characterization of potential biomarkers in tamoxifen resistance in breast cancer

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

IP6K2 predicts favorable clinical outcome of primary breast cancer

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

S-phase fraction is a prognostic factor in stage I breast carcinoma

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit

C-erbB-2 overexpression and survival in early onset breast cancer

Expression of COX-2 and steroid converting enzymes in breast cancer

Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer

Long-term benefit from tamoxifen therapy for patients with Luminal A and Luminal B breast cancer: Retrospective analysis of the STO-3 trial

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer

c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up

HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

A comparison between flow cytometric assessment of S-phase fraction and Nottingham histologic grade as prognostic instruments in breast cancer

Wwox expression may predict benefit from adjuvant tamoxifen in randomized breast cancer patients

Cytoplasmic p21 WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer

Aktive Filter

Suchergebnisse filtern